
MORPHOSYS AG (DELISTED)
Acción · DE0006632003 · 663200 (XETR)
Sin cotización
n/a
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
- | - | - | - | 0,00 % | 0,52 % | -39,39 % |
Perfil de la empresa para MORPHOSYS AG Acción
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Fondos invertidos
Los siguientes fondos han invertido en: MORPHOSYS AG invertido:
Fondo | Vol. en millones 3,72 | Porcentaje (%) 1,18 % |
Fondo | Vol. en millones 12.878,53 | Porcentaje (%) 1,18 % |
Fondo | Vol. en millones 6.502,84 | Porcentaje (%) 0,51 % |
Fondo | Vol. en millones 12,61 | Porcentaje (%) 0,46 % |
Fondo | Vol. en millones 2.364,24 | Porcentaje (%) 0,28 % |
Datos de la empresa
Nombre MORPHOSYS AG
Empresa MorphoSys AG
Sitio web
https://www.morphosys.com
Mercado principal
XETRA

WKN 663200
ISIN DE0006632003
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Mr. Arkadius Pichota M.B.A., Ph.D.
Capitalización de mercado 3 Mrd.
País Alemania
Moneda EUR
Empleados 0,5 T
Dirección Semmelweisstrasse 7, 82152 Planegg
Fecha de OPV 1999-03-10
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | MOR.F |
XETRA | MOR.DE |
Otras acciones
Los inversores que tienen MORPHOSYS AG también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.